Answers are grounded in this paper and cite their sources.
Background Pleural effusion is a common finding in hospital admissions. Tissue biopsy is considered more definitive for obtaining a larger volume of tissue. The search for non-invasive identification procedures with high sensitivity and specificity has attracted considerable clinical interest. Our study aims to assess the diagnostic significance of tumor M2-pyruvate kinase (TuM2-PK) levels in pleural effusion and serum in patients with benign and malignant exudative pleural effusion. Methods This cross-sectional study was conducted in the Chest Department in conjunction with the Clinical Pathology Department, Faculty of Medicine, Cairo University. In the study, 88 patients were divided into two groups: Group 1 comprised 44 patients with malignant pleural effusion, and Group 2 comprised 44 patients with non-malignant exudative pleural effusion. All patients underwent history taking, full clinical examination, laboratory tests, and chest radiography. Serum and pleural fluid samples were collected to assess tumor M2-pyruvate kinase levels. Pleural biopsy was performed by medical thoracoscopy or image-guided pleural biopsy and histopathological examination of the biopsy. Results The study showed that serum M2-pyruvate kinase was significantly higher in patients with malignant effusion (p-value 0.042), with a cutoff value of 1.25 pg/µL, sensitivity of 63.6%, and specificity of 52.3%. Whereas pleural Fluid M2-pyruvate level and serum M2-pyruvate ratio (P/S) were statistically insignificant between the two groups. Conclusion Serum TuM2-PK showed limited diagnostic performance for detecting malignant pleural effusion and is insufficiently accurate to distinguish malignant from benign pleural effusion reliably.
No takes yet. Share an insight, caveat, or question.
Mazid et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: